A detailed history of Arrowstreet Capital, Limited Partnership transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 3,331,575 shares of BMY stock, worth $138 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
3,331,575
Previous 491,267 578.16%
Holding current value
$138 Million
Previous $25.2 Million 616.75%
% of portfolio
0.17%
Previous 0.03%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$47.98 - $54.4 $136 Million - $155 Million
2,840,308 Added 578.16%
3,331,575 $181 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $15.5 Million - $18.5 Million
319,553 Added 186.1%
491,267 $25.2 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $9.94 Million - $11.1 Million
171,714 New
171,714 $9.97 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $47.4 Million - $53.8 Million
721,425 Added 272.77%
985,908 $68.3 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $678,773 - $803,764
-9,912 Reduced 3.61%
264,483 $19 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $35,671 - $21.1 Million
274,395 New
274,395 $19.5 Million
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $158 Million - $174 Million
-2,181,468 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $245 Million - $294 Million
-3,985,365 Reduced 64.63%
2,181,468 $159 Million
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $7.09 Million - $8.27 Million
132,211 Added 2.19%
6,166,833 $385 Million
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $282 Million - $331 Million
4,769,885 Added 377.14%
6,034,622 $357 Million
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $78.3 Million - $85.3 Million
1,264,737 New
1,264,737 $84.5 Million
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $62.7 Million - $69.5 Million
-1,092,148 Closed
0 $0
Q2 2020

Aug 12, 2020

SELL
$54.82 - $64.09 $61.1 Million - $71.4 Million
-1,113,891 Reduced 50.49%
1,092,148 $64.2 Million
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $102 Million - $149 Million
2,206,039 New
2,206,039 $123 Million
Q4 2019

Feb 13, 2020

SELL
$49.21 - $64.19 $138 Million - $180 Million
-2,804,704 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $283 Million - $335 Million
-6,614,511 Reduced 70.22%
2,804,704 $142 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $237 Million - $262 Million
-5,319,461 Reduced 36.09%
9,419,215 $427 Million
Q1 2019

May 15, 2019

SELL
$45.12 - $53.8 $1.18 Million - $1.41 Million
-26,183 Reduced 0.18%
14,738,676 $703 Million
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $14.6 Million - $18.9 Million
299,601 Added 2.07%
14,764,859 $767 Million
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $29.4 Million - $33.1 Million
532,413 Added 3.82%
14,465,258 $898 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $372 Million - $464 Million
7,362,915 Added 112.07%
13,932,845 $771 Million
Q1 2018

May 14, 2018

BUY
$59.92 - $68.98 $4.54 Million - $5.22 Million
75,710 Added 1.17%
6,569,930 $416 Million
Q4 2017

Feb 09, 2018

BUY
$59.94 - $65.35 $85 Million - $92.6 Million
1,417,638 Added 27.93%
6,494,220 $398 Million
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $280 Million - $324 Million
5,076,582
5,076,582 $324 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $88.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Arrowstreet Capital, Limited Partnership Portfolio

Follow Arrowstreet Capital, Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.